OGEN Stock - Oragenics, Inc.
Unlock GoAI Insights for OGEN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | $-22,107,563 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-10,558,815 | $-20,904,903 | $-14,420,768 | $-15,771,018 | $-26,641,456 |
| Net Income | $-10,567,918 | $-20,655,737 | $-14,288,389 | $-15,711,614 | $-26,430,699 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.60 | $-9.18 | $-7.11 | $-8.09 | $-28.05 |
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
Visit WebsiteEarnings History & Surprises
OGENEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 7, 2026 | — | — | — | — |
Q4 2025 | Nov 7, 2025 | — | $-1.96 | — | — |
Q3 2025 | Aug 8, 2025 | — | $-3.10 | — | — |
Q2 2025 | May 9, 2025 | — | $-3.60 | — | — |
Q1 2025 | Mar 14, 2025 | — | $-0.11 | — | — |
Q4 2024 | Nov 13, 2024 | — | $-0.38 | — | — |
Q3 2024 | Aug 9, 2024 | — | $-0.51 | — | — |
Q2 2024 | May 15, 2024 | — | $-0.70 | — | — |
Q1 2024 | Mar 29, 2024 | $-3.00 | $-5.48 | -82.7% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-3.00 | $-0.85 | +71.7% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-3.00 | $-1.51 | +49.7% | ✓ BEAT |
Q2 2023 | May 12, 2023 | $-3.00 | $-1.41 | +53.0% | ✓ BEAT |
Q1 2023 | Mar 29, 2023 | $-2.40 | $-0.12 | +94.9% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-3.00 | $-1.80 | +40.0% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-1.44 | $-1.80 | -25.0% | ✗ MISS |
Q2 2022 | May 13, 2022 | $-1.20 | $-2.99 | -150.0% | ✗ MISS |
Q1 2022 | Mar 24, 2022 | $-0.80 | $-1.20 | -50.0% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-0.00 | $-2.40 | -358109.0% | ✗ MISS |
Q3 2021 | Aug 16, 2021 | $-1.44 | $-1.80 | -25.0% | ✗ MISS |
Q2 2021 | May 3, 2021 | $-2.69 | $-2.99 | -11.1% | ✗ MISS |
Latest News
Reported November 7, 2025: Oragenics Q3 EPS $(1.96) Up From $(11.32) YoY
📈 PositiveOragenics Regains Nasdaq Compliance
📈 PositiveOragenics Collaborates With Receptor.AI To Accelerate Potential Development Of Expanded Pharmaceutical-Candidate Portfolio For Potential Conditions Affecting Brain Health
📈 PositiveOragenics announces $20M preferred stock offering; shares surge over 138%
📈 PositiveOragenics announces 1-for-30 reverse stock split
➖ NeutralFrequently Asked Questions about OGEN
What is OGEN's current stock price?
What is the analyst price target for OGEN?
What sector is Oragenics, Inc. in?
What is OGEN's market cap?
Does OGEN pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to OGEN for comparison